≡ Risteys
R9

Documentation Changelog GitHub Contact & Feedback

Immunodeficiencies

DOID MESH PheWeb

D3_IMMUDEF

No definition available.

Endpoint definition

↥
FinnGen phenotype data

392423 individuals

diagram downward connector

Apply sex-specific rule None

392423

diagram downward connector

Check conditions None

392423

diagram downward connector

Check pre-conditions, main-only, mode, registry filters None

0 out of 7 registries used, show all original rules.

0

diagram downward connector

Check minimum number of events None

0

diagram downward connector
diagram bullet diagram downward connector

Include endpoints

1408

diagram downward connector
diagram bullet diagram downward connector

Remove individuals based on genotype QC

1350

diagram downward connector
D3_IMMUDEF

Control definitions

Controls for this endpoint are individuals that are not cases.

Extra metadata

Level in the ICD hierarchy C
First used in FinnGen datafreeze DF2

No data for upset plot.

No data for upset table.

Similar endpoints

↥

List of similar endpoints to Immunodeficiencies based on the number of shared cases.

Venn diagram with an highlighted set fully inside another set Broader endpoints:

Venn diagram with a set fully inside an highlighted set Narrower endpoints:

Show all endpoint correlations

Summary Statistics

↥

Key figures

All Female Male
Number of individuals 1350 861 489
Unadjusted prevalence (%) 0.36 0.41 0.29
Mean age at first event (years) 47.80 46.20 50.62

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.11 7.19 [5.02, 10.30] 6.2e-27 163
15 years 0.02 3.28 [2.31, 4.65] 2.9e-11 57
5 years 0.01 8.04 [5.64, 11.44] 6.4e-31 52
1 year 0.01 25.90 [17.25, 38.87] 1.4e-55 34

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: D3_IMMUDEF – Immunodeficiencies
GWS hits:

Survival analyses between endpoints

↥

Plot

before Immunodeficiencies
after Immunodeficiencies

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Immunodeficiencies

↥

Endpoint not on priority list, no data to show.